Department of Pathology, Eulji University Hospital, Eulji University School of Medicine, Daejeon, Republic of Korea.
Department of Internal Medicine, Eulji Hospital, Eulji University School of Medicine, Seoul, Republic of Korea.
Int J Biol Markers. 2019 Sep;34(3):276-283. doi: 10.1177/1724600819858753. Epub 2019 Jul 24.
The aim of this study was to evaluate the clinicopathological significance and prognostic role of programmed death-1 ligand 2 (PD-L2) expression in colorectal cancer according to intratumoral components.
We used immunohistochemical analysis to investigate the impact of PD-L2 expression on clinicopathological characteristics and survival in 264 human colorectal cancer tissues. We also evaluated the correlation between PD-L2 expression and PD-L1 expression.
PD-L2 was expressed in 17.4% of the tumors (T-PD-L2) and in 19.3% of the immune cells (I-PD-L2) of the 264 CRC tissues. I-PD-L2 expression was significantly correlated with favorable tumor behaviors, including lower pathologic tumor stage, less lymph node metastasis, less distant metastasis, and lower pathologic tumor node metastasis stage. There was no significant correlation between I-PD-L2 expression and T-PD-L2 expression ( = 0.091). However, I-PD-L2 expression was correlated with PD-L1 expression in the immune cells ( < 0.001). There was also a significant correlation between high Immunoscore and I-PD-L2, but not T-PD-L2 ( < 0.001 and = 0.190, respectively). The prognosis was better for patients who expressed I-PD-L2 than for patients who did not. In patients who expressed I-PD-L2, there was a significant difference in the survival rate between subgroups according to the presence or absence of T-PD-L2 expression.
Our results suggest that I-PD-L2 expression is significantly correlated with favorable tumor behaviors and better survival rates. There is also a significant correlation between PD-L2 expression and PD-L1 expression in immune cells.
本研究旨在根据肿瘤内成分评估程序性死亡配体 2（PD-L2）在结直肠癌中的临床病理意义和预后作用。
我们使用免疫组织化学分析来研究 PD-L2 表达对 264 个人结直肠癌组织临床病理特征和生存的影响。我们还评估了 PD-L2 表达与 PD-L1 表达之间的相关性。
在 264 例 CRC 组织中，PD-L2 在 17.4%的肿瘤（T-PD-L2）和 19.3%的免疫细胞（I-PD-L2）中表达。I-PD-L2 表达与有利的肿瘤行为显著相关，包括较低的病理肿瘤分期、较少的淋巴结转移、较少的远处转移和较低的病理肿瘤淋巴结转移分期。I-PD-L2 表达与 T-PD-L2 表达之间无显著相关性（=0.091）。然而，I-PD-L2 表达与免疫细胞中的 PD-L1 表达相关（<0.001）。免疫评分高与 I-PD-L2 表达相关，而与 T-PD-L2 表达无关（分别为<0.001 和=0.190）。表达 I-PD-L2 的患者预后好于不表达 I-PD-L2 的患者。在表达 I-PD-L2 的患者中，根据 T-PD-L2 表达的存在与否，生存率存在显著差异。
我们的结果表明，I-PD-L2 表达与有利的肿瘤行为和较好的生存率显著相关。PD-L2 表达与免疫细胞中的 PD-L1 表达也存在显著相关性。
